Literature DB >> 31531835

The incidence and risk factors of hypofibrinogenemia in cardiovascular surgery.

Toshihiko Nishi1, Masato Mutsuga2, Toshiaki Akita2, Yuji Narita2, Kazuro Fujimoto2, Yoshiyuki Tokuda2, Sachie Terazawa2, Hideki Ito2, Kimitoshi Nishiwaki3, Akihiko Usui2.   

Abstract

OBJECTIVE: Cardiovascular surgery often causes massive bleeding due to coagulopathy, with hypofibrinogenemia being a major causative factor. We assessed the intraoperative incidence of hypofibrinogenemia and explored predictors of hypofibrinogenemia.
METHODS: The intraoperative serum fibrinogen level (SFL) was routinely measured in 872 consecutive patients [mean age: 66.9 ± 13.3 years; 598 men (68.6%)] undergoing cardiovascular surgery from July 2013 to November 2016 at Nagoya University Hospital. There were 275 aortic surgeries, 200 cases of coronary artery bypass grafting (CABG), 334 valvular surgeries and 63 other surgeries. We estimated hypofibrinogenemia incidence (intraoperative lowest SFL ≤ 150 mg/dL) and identified its predictors by a logistic regression analysis.
RESULTS: The average intraoperative lowest SFL of all cases, aortic surgery, CABG and valvular surgery was 185 ± 71, 156 ± 65, 198 ± 69 and 198 ± 68 mg/dL, respectively. Aortic surgery had a significantly lower intraoperative lowest SFL than CABG (p < 0.001) and valvular surgery (p < 0.001). The incidence of hypofibrinogenemia was 32.8%, 50.2%, 26.5% and 22.8% in all cases, aortic surgery, CABG and valvular surgery, respectively. The predictors of hypofibrinogenemia were the preoperative SFL, re-do surgery and perfusion time. A receiver operating characteristics curve analysis showed that the best preoperative SFL cutoff value for predicting hypofibrinogenemia was 308.5 mg/dL. Assuming preoperative SFL 300 mg/dL as the cutoff, the odds ratio for hypofibrinogenemia was 7.22 (95% confidence interval 5.26-9.92, p < 0.001).
CONCLUSIONS: The incidence of hypofibrinogenemia in aortic surgery was high. The preoperative SFL, re-do surgery and perfusion time were identified as predictors for hypofibrinogenemia. Intraoperative measurement of SFL is important for detecting hypofibrinogenemia and applying appropriate and prompt transfusion treatment.

Entities:  

Keywords:  Cardiovascular surgery; Coagulopathy; Fibrinogen; Hemostasis

Year:  2019        PMID: 31531835     DOI: 10.1007/s11748-019-01201-8

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  23 in total

1.  Preoperative coagulation studies to predict blood component usage in coronary artery bypass graft surgery.

Authors:  S Josefy; R Briones; B J Bryant
Journal:  Immunohematology       Date:  2011

2.  Is preoperative fibrinogen predictive for postoperative bleeding after coronary artery bypass grafting surgery?

Authors:  Daniel Bolliger; Meredith Gonsahn; Jerrold H Levy; Willis H Williams; Kenichi A Tanaka
Journal:  Transfusion       Date:  2009-09       Impact factor: 3.157

3.  Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: a randomized pilot trial.

Authors:  Filomena R B G Galas; Juliano P de Almeida; Júlia T Fukushima; Jean Louis Vincent; Eduardo A Osawa; Suely Zeferino; Lígia Câmara; Vanessa A Guimarães; Marcelo B Jatene; Ludhmila A Hajjar
Journal:  J Thorac Cardiovasc Surg       Date:  2014-04-18       Impact factor: 5.209

Review 4.  Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy.

Authors:  Jerrold H Levy; Ian Welsby; Lawrence T Goodnough
Journal:  Transfusion       Date:  2013-10-09       Impact factor: 3.157

5.  Low preoperative fibrinogen plasma concentration is associated with excessive bleeding after cardiac operations.

Authors:  Katarina Waldén; Anders Jeppsson; Salmir Nasic; Erika Backlund; Martin Karlsson
Journal:  Ann Thorac Surg       Date:  2014-02-06       Impact factor: 4.330

6.  Fibrinogen concentrate reduces intraoperative bleeding when used as first-line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo-controlled trial.

Authors:  Niels Rahe-Meyer; Alexander Hanke; Dirk S Schmidt; Christian Hagl; Maximilian Pichlmaier
Journal:  J Thorac Cardiovasc Surg       Date:  2013-03       Impact factor: 5.209

Review 7.  Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data.

Authors:  C Solomon; A Gröner; J Ye; I Pendrak
Journal:  Thromb Haemost       Date:  2014-12-11       Impact factor: 5.249

8.  Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery.

Authors:  Niels Rahe-Meyer; Cristina Solomon; Michael Winterhalter; Siegfried Piepenbrock; Kenichi Tanaka; Axel Haverich; Maximilian Pichlmaier
Journal:  J Thorac Cardiovasc Surg       Date:  2009-05-17       Impact factor: 5.209

9.  Impact of the intraoperative use of fibrinogen concentrate for hypofibrinogenemia during thoracic aortic surgery.

Authors:  Yoshimori Araki; Akihiko Usui; Hideki Oshima; Tomonobu Abe; Kazuro Fujimoto; Masato Mutsuga; Yoshiyuki Tokuda; Sachie Terazawa; Kei Yagami; Hideki Ito
Journal:  Nagoya J Med Sci       Date:  2015-02       Impact factor: 1.131

10.  Factors Associated with Low Admission Platelet Count in Adults with Acute Aortic Dissection.

Authors:  Shuwen Li; Jiakai Lu; Weiping Cheng; Junming Zhu; Mu Jin
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-12-18       Impact factor: 1.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.